All posts by student

‘Grey’s Anatomy’ star bids farewell to show with emotional note – CNN

Dr. Stephanie Edwards has checked out of Grey Sloan Memorial Hospital.

At the end of last week's episode, viewers were left wondering what the character's fate would be after she and a young girl were left trapped in the same room as a massive explosion.

Stephanie, who is played by actress Jerrika Hinton, and the young girl survived. They suffered burns, smoke inhalation and various other wounds from which they were told they'd recover. (The deranged patient who Stephanie lit on fire, inadvertently causing the explosion, did not survive -- as one might imagine.)

But Stephanie was not eager to get back into the operating room.

The harrowing experience -- coupled with her history as a sick child -- made her realized she didn't want to spend any more time in hospitals. She told mentor Dr. Webber (James Pickens Jr.) that she needed to get outside the sterile walls and live.

Thus, Stephanie walked away with the rarest of "Grey's Anatomy" endings: something not completely horrific or tragic or heartbreaking.

Hinton took to Instagram to mark the moment.

"I am eternally thankful for five seasons of #GreysAnatomy and a graceful departure that underscores the courage it takes to choose yourself," Hinton wrote. "That Stephanie literally walks through fire to reach freedom -- her freedom -- inspires me."

Hinton had been rumored to be leaving the long-running ABC drama, but her departure was not confirmed until Thursday night.

In another post, Hinton spoke more directly to the fans "who look like me," saying, "I hear you when you say I represent you."

"It has been the greatest honor to show us *us*," she wrote. "Eking out this kind of #representation on a weekly basis within a medium that continues to correlate value with proximity to whiteness is a feat. That I got to deliver a relatable, recognizable and unvarnished #StephanieEdwards who looks and feels like women I know who are people rather than ideas has been worth more than you know."

She added: "Thank the tv gods for #TGIT."

"Jerrika has shared so much of herself with Stephanie and I am incredibly proud of the journey we've taken together," she wrote.

"Grey's Anatomy" returns for Season 14 in the fall, with a new firefighter-themed spinoff set to debut in mid-season.

Continued here:
'Grey's Anatomy' star bids farewell to show with emotional note - CNN

What Does it Mean to Be a Species? Genetics is Changing the Answer – Smithsonian

Ornithologist John Gould's illustrations of finches collected by Charles Darwin on the Galpagos Islands show the physical differences that the men relied on in dividing them into different species.

For Charles Darwin, "species" wasan undefinable term, "one arbitrarily given for the sake of convenience to a set of individuals closely resembling each other." That hasn't stopped scientists in the 150 years since then from trying, however. When scientists today sit down to study a new form of life, they apply any number ofmore than 70 definitionsof what constitutes a speciesand each helps get at a different aspect of what makes organisms distinct.

In a way, this plethora of definitions helps prove Darwins point: The idea of a species is ultimately a human construct. With advancing DNA technology, scientists are now able to draw finer and finer lines between what they consider species by looking at the genetic code that defines them. How scientists choose to draw that line depends on whether their subject is an animal or plant; the tools available; and the scientists own preference and expertise.

Now, as new species are discovered and old ones thrown out, researchers want to know: How do we define a species today? Lets look back at the evolution of the concept and how far its come.

Perhaps the most classic definition is a group of organisms that can breed with each other to produce fertile offspring, an idea originally set forthin 1942by evolutionary biologist Ernst Mayr. While elegant in its simplicity, this concept has since come under fire by biologists, who arguethat it didn't apply to many organisms, such as single-celled ones that reproduce asexually, or those that have been shown to breed with other distinct organisms to create hybrids.

Alternativesarose quickly. Some biologists championed an ecologicaldefinition that assigned species according to the environmental niches they fill (this animal recycles soil nutrients, this predator keeps insects in check). Others asserted that a species was a set of organisms with physical characteristics that were distinct from others (the peacock's fanned tail, the beaks of Darwin's finches).

The discovery of DNA's double helix prompted the creation of yet another definition, one in which scientists could look for minute genetic differences and draw even finer lines denoting species. Based ona 1980 bookby biologists Niles Eldredge and Joel Cracraft, under the definition of a phylogenetic species, animal species now can differ by just 2 percent of their DNA to be considered separate.

"Back in 1996, the world recognized half the number of species of lemur there are today," says Craig Hilton-Taylor, who manages the International Union for the Conservation of Nature's Red Listof threatened species. (Today there are more than 100 recognized lemur species.) Advances in genetic technology have given the organization a much more detailed picture of the world's species and their health.

These advances have also renewed debates about what it means to be a species, as ecologists and conservationistsdiscover that many species that once appeared singularare actually multitudes. Smithsonian entomologistJohn Burnshas used DNA technology to distinguish a number of so-called "cryptic species"organisms that appear physically identical to a members of a certain species, but have significantly different genomes. In a2004 study, he was able to determine that a species of tropical butterfly identified in 1775 actually encompassed 10 separate species.

In 2010, advanced DNA technology allowed scientists to solve an age-old debate over African elephants. By sequencing therarer and more complex DNA from the nuclei of elephant cells,instead of the more commonly used mitochondrial DNA, they determined thatAfrican elephants actually comprised two separate speciesthat diverged millions of years ago.

"You can no more call African elephants the same species as you can Asian elephants and the mammoth," David Reich, a population geneticist and lead author on the study, told Nature News.

In the wake of these and other paradigm-shifting discoveries, Mayrs original concept is rapidly falling apart. Those two species of African elephants, for instance, kept interbreeding as recently as 500,000 years ago. Another example falls closer to home: Recent analyses of DNA remnants in the genes of modern humans have found that humans and Neanderthalsusually thought of as separate species thatdiverged roughly 700,000 years agointerbred as recently as 100,000 years ago.

So are these elephants and hominidsstill separate species?

This isn't just an argument of scientific semantics. Pinpointing an organism's species is critical for any efforts to protect that animal, especially when it comes to government action. A species that gets listed on the U.S. Endangered Species Act, for example,gains protectionfrom anydestructive actions from the government and private citizens.These protections would be impossible to enforce without the ability to determine which organisms are part of that endangered species.

At the same time,advances in sequencing techniques and technologyare helping todays scientists better piece together exactly which species are being impacted by which human actions.

"We're capable of recognizing almost any species [now]," saysMary Curtis, a wildlife forensic scientist who leads the genetics team at the U.S. Fish and Wildlife Service'sForensics Laboratory. Her lab is responsible for identifying any animal remains or products that are suspected to have been illegally traded or harvested. Since adopting DNA sequencing techniques more than 20 years ago, the lab has been able to make identifications much more rapidly, and increase the number of species it can reliably recognize by the hundreds.

"A lot of the stuff we get in in genetics has no shape or form," Curtis says. The lab receives slabs of unidentified meat, crafted decorative items or even the stomach contents of other animals. Identifying these unusual items is usually out of the reach of taxonomic experts using body shape, hair identification and other physical characteristics. "We can only do that with DNA," Curtis says.

Still, Curtis, who previously studied fishes, doesn't discount the importance of traditional taxonomists. "A lot of the time we're working together," she says. Experienced taxonomists can often quickly identify recognizable cases, leaving the more expensive DNA sequencing for the situations that really need it.

Not all ecologists are sold on these advances. Some express concerns about "taxonomic inflation," as the number of species identified or reclassified continues to skyrocket. They worry that as scientists draw lines based on the narrow shades of difference that DNA technology enables them to see, the entire concept of a species is being diluted.

"Not everything you can distinguish should be its own species," as German zoologist Andreas Wiltingtold the Washington Post in 2015. Wilting hadproposed condensing tigers into just two subspecies, from the current nine.

Other scientists are concernedabout the effects that reclassifying once-distinct species can have on conservation efforts. In 1973, the endangered dusky seaside sparrow, a small bird once found in Florida, missed out on potentially helpful conservation assistance by beingreclassified as a subspeciesof the much more populous seaside sparrow . Less than two decades later, the dusky seaside sparrow was extinct.

Hilton-Taylor isnt sure yet when or how the ecological and conservation communities will settle on the idea of a species. But he does expect that DNA technology will have a significant impacton disrupting and reshaping the work of those fields. Lots of things are changing, Hilton-Taylor says. That's the world we're living in.

This uncertainty is in many ways reflective of the definition of species today too, Hilton-Taylor says. The IUCN draws on the expertise of various different groups and scientists to compile data for its Red List, and some of those groups have embraced broader or narrower concepts of what makes a species, with differing reliance on DNA. There's such a diversity of scientists out there, Hilton-Taylor says. We just have to go with what we have.

Original post:
What Does it Mean to Be a Species? Genetics is Changing the Answer - Smithsonian

Seattle Genetics cancels Immunomedics deal – Chemistry World (subscription)

US biotechnology firms Seattle Genetics and Immunomedics have broken off their planned licensing deal for Immunomedics experimental cancer antibody IMMU-132 (sacituzumab govitecan).

The deal had been hampered by legal action from Immunomedics shareholders, including investment fund venBio. Immunomedics has proposed to settle this litigation following cancellation of the deal. As part of the settlement agreement, Immunomedicss chief executive, Cynthia Sullivan, will leave the company. Founder David Goldenberg will also step down as chief science officer, although he will retain a seat on the board. Behzad Aghazadeh from venBio has assumed the role of Chairman.

View original post here:
Seattle Genetics cancels Immunomedics deal - Chemistry World (subscription)

Using genomics to fight deadly parasitic disease – UNM Newsroom

An international team of researchers, led by University of New Mexico Associate Professor Coenraad Adema, is now one step closer to eliminating a deadly parasitic disease responsible for killing hundreds of thousands of people around the world every year.

The research article, Whole genome analysis of a schistosomiasis-transmitting freshwater snail, published in Nature Communications this week, gives the scientific community an in-depth look of the sequenced genome of Biomphalaria glabrata, a tropical Rams Horn snail.

Sequencing and characterizing the genome of this snail has given us a lot of information into its biology, said Adema, who is also part of UNMs Center for Evolutionary and Theoretical Immunology (CETI) that has played a pivotal role in this project. It has informed us on animal evolution and supports the drive to minimize the impact of infectious disease on global health.

This snail, which lives only in tropical climates, plays a significant role in the lifecycle of a parasitic disease called schistosomiasis, also known as snail fever or bilharzia. The parasite infects the snail early on its life, essentially taking over the snails body, impacting its reproductive and metabolic processes. Once fully developed, the parasite leaves the snail, later infecting a human host through contact in water.

After malaria, this is the worst parasitic disease on the planet. So, being able to do work that may help improve global human health outcomesis a very important motivation for my research. Dr. Coen Adema, Dept. of Biology

According to Adema, if researchers can better understand how the snail/parasite interaction works, they may be able to stop it altogether, cutting the snail out of the parasites lifecycle. And, because the snail is a critical part of the organisms development; without it, the parasite cannot fully mature and infect humans.

Understanding the animals genetic makeup is a critical component in being able to understand these interactions something that is now possible thanks to this international team of researchers and support from the National Human Genome Research Institute of NIH for the sequencing effort.

Understanding the snails genome gives us many avenues to cut the snail out of this parasites lifecycle, Adema said. Which one day may lead to the elimination of this disease."

Schistosomiasis is a chronic parasitic disease. According to the World Health Organization (WHO), more than 66 million people were reported to have been treated for the disease in 2015, with another 218 million people requiring preventative treatment. On top of that, nearly a quarter of a million people die from snail fever every year, just in sub-Saharan Africa.

The disease is also extremely easy to contract, which is part of the reason why it impacts so many people. Once the parasite leaves its host snail, its able live in a body of water before breaking through skin to infect a human body. In Africa for example, simply putting your hand in the Nile River can lead to infection. The WHO hopes to eliminate snail fever by 2025 a goal that is made increasingly more likely because of this investigation led by UNM.

After malaria, this is the worst parasitic disease on the planet, said Adema. So, being able to do work that may help improve global human health outcomes it is a very important motivation for my research.

More than 100 researchers from 50 institutions around the world are a part of this study and latest publication a testament to how significant and wide-reaching this disease and its overall impact is. The international expertise in parasitology and invertebrate biology at UNM is underscored by important contributions of nearly a dozen different faculty, graduate students and research scientists from the Biology Department that are also part of this effort.

Adema says several of his international colleagues are already exploring new, different ways to use the snails genome to fight the disease. And while the parasite and corresponding illness are the main target of this research, there is also much more to learn from the genome.

This is an important contribution to better understanding infectious disease, he said. It also gives us information on regulation of gene expression, comparative immunology, embryology, general biology of snails, animal evolution and many other things."

View post:
Using genomics to fight deadly parasitic disease - UNM Newsroom

Ovation Fertility Presenting One Embryo-One Baby Success … – PR Web (press release)

We are pleased to share industry-recognized, pioneering IVF research performed by Ovation Fertility and to provide continuing education to clinical and medical laboratory professionals across the nation. Nate Snyder, CEO, Ovation Fertility

LOS ANGELES, CA (PRWEB) May 19, 2017

Ovation Fertility scientists work is being showcased at the annual meeting and educational conference of the American Association of Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today and Saturday (May 19-20) at the Galleria Hotel in Houston. The conference reinforces AABs commitment to excellence in clinical laboratory services and regulations.

We are pleased to share industry-recognized, pioneering IVF research performed by Ovation Fertility and to provide continuing education to clinical and medical laboratory professionals across the nation, says Nate Snyder, CEO, Ovation Fertility. Attendees benefit from learning about the successes brought about by the collaborative mindshare of Ovation Fertility IVF and genetics labs, working in tandem with our partner physician practices.

Mitchel C. Schiewe, Ph.D., HCLD, who directs Ovation Fertilitys IVF lab in Newport Beach, notes that by working together across its network of experts, Ovation Fertility developed reproductive technology solutions that make achieving pregnancy through IVF more effective, affordable and financially accessible.

Ovation Fertility IVF Labs, Partner Practices Join Forces

The two abstracts being presented at the conference show research performed by Ovation Fertility in conjunction its partner physician practices.

1. Striving for One Embryo-One Baby: How the Integration of Vitrification and Preimplantation Genetic Screening (PGS) Technologies Has Impacted Society

Technical Supervisor Shane Zozula of Ovation Fertility Newport Beach is presenting a poster based on Ovation Fertilitys founding philosophy to achieve successful pregnancy one healthy baby at a time. Although advanced embryo culturing has led to favorable pregnancy results using fresh embryo transfers, they often were the result of multiple embryo transfers, resulting in high-risk pregnancies with twins and triplets. Through elective vitrification and the adoption of blastocyst biopsy/PGS, Ovation Fertility has improved the quality of patient care by transferring fewer embryos, reducing miscarriages and increasing healthy singleton live births.

The findings were produced collaboratively by researchers at Ovation Fertility labs in Newport Beach and Las Vegas, Southern California Center for Reproductive Medicine, and The Fertility Center of Las Vegas. They include Shane Zozula; John Whitney; Robert E. Anderson, M.D.; and Schiewe. Forest Garner provided study design and statistics support.

2. Comparative Human Blastocyst Repeat Vitrification (rVTF): Effect of Device Type (Cryolock versus microSecure) by Solution Used (DMSO/EG versus Glycerol/EG) on Post-warming Viability

Vitrification of human embryos has evolved into a highly reliable and efficient process in many assisted reproductive-technology laboratories worldwide. Over the past several years, Schiewe has strived to better understand the physical and chemical relationships of vitrification treatments by using a revitrification model to define tolerance thresholds for post-warming survival/viability. At the AAB/CRB conference, embryologist RaeAnne vanTol is making the oral presentation showing the resiliency of human blastocysts to various cryopreservation agents and devices. The subset of data being presented is part of a larger collaborative study between Ovation Fertility labs in Newport Beach and Nashville that will be presented at the European Society of Human Reproduction and Embryology annual conference in July.

Additional authors include Shane Zozula, Kelley Waggoner and Schiewe, all of Ovation Fertility Newport Beach.

Collaboration Leads to Success

According to Snyder, We are proud of the collaborative efforts among Ovation Fertility labs and partner practices. The greatest advances in reproductive medicine result from the collective knowledge and shared experience of fertility professionals, working as a cohesive team rather than as individuals. The research presented by Ovation Fertility in Houston will benefit all patients who are considering using IVF to build their families.

About Ovation Fertility Ovation Fertility Founded in 2015 by a coalition of thought-leading reproductive endocrinologists and scientists, Ovation Fertility is a national fertility service provider offering a suite of state-of-the-art assisted reproductive technology services to aspiring parents, including embryology, andrology and genetic testing as part of the in vitro fertilization process. Ovation Fertility partners with physicians who are committed to reducing the average cost of a live birth through IVF by advancing industry standards in fertility treatment. For more information, visit http://www.ovationfertility.com.

Share article on social media or email:

Originally posted here:
Ovation Fertility Presenting One Embryo-One Baby Success ... - PR Web (press release)

Social networking for the proteome, upgraded | HMS – Harvard Medical School (registration)

Harvard Medical School researchers have mapped the interaction partners for proteins encoded by more than 5,800 genes, representing over a quarter of the human genome, according to a new study published online in Nature on May 17.

The network, dubbed BioPlex 2.0, identifies more than 56,000 unique protein-to-protein interactions87 percent of them previously unknownthe largest such network to date.

Get HMS news here

BioPlex reveals protein communities associated with fundamental cellular processes and diseases such as hypertension and cancer, and highlights new opportunities for efforts to understand human biology and disease.

The work was done in collaboration with Biogen, which also provided partial funding for the study.

A gene isnt just a sequence of a piece of DNA. A gene is also the protein it encodes, and we will never understand the genome until we understand the proteome, said co-senior author Wade Harper, the Bert and Natalie Vallee Professor of Molecular Pathology and chair of the Department of Cell Biology at HMS. BioPlex provides a framework with the depth and breadth of data needed to address this challenge.

This project is an atlas of human protein interactions, spanning almost every aspect of biology, said co-senior author Steven Gygi, professor of cell biology and director of the Thermo Fisher Center for Multiplexed Proteomics at HMS. It creates a social network for each protein and allows us to see not only how proteins interact, but also possible functional roles for previously unknown proteins.

HMS scientists are mapping interaction networks throughoutthe human proteome. Edward Huttlin, instructorin cell biology, explains. Video: Elizabeth Cooney

Bait and prey

Of the roughly 20,000 protein-coding genes in the human genome, scientists have studied only a fraction in detail. To work toward a description of the entire cast of proteins in a cell and the interactions between themknown as the proteome and interactome, respectivelya team led by Harper and Gygi developed BioPlex, a high-throughput approach for the identification of protein interplay.

BioPlex uses so-called affinity purification, in which a single tagged bait protein is expressed in human cells in the laboratory. The bait protein binds with its interaction partners, or prey proteins, which are then fished out from the cell and analyzed using mass spectrometry, a technique that identifies and quantifies proteins based on their unique molecular signatures. In 2015, an initial effort (BioPlex 1.0) used approximately 2,600 different bait proteins, drawn from the Human ORFeome database, to identify nearly 24,000 protein interactions.

In the current study, the team expanded the network to include a total of 5,891 bait proteins, which revealed 56,553 interactions involving 10,961 different proteins. An estimated 87 percent of these interactions have not been previously reported.

Guilt by association

By mapping these interactions, BioPlex 2.0 identifies groups of functionally related proteins, which tend to cluster into tightly interconnected communities. Such guilt-by-association analyses suggested possible roles for previously unknown proteins, as these communities often commingle proteins with both known and unknown functions.

The team mapped numerous protein clusters associated with basic cellular processes, such as DNA transcription and energy production, and a variety of human diseases. Colorectal cancer, for example, appears to be linked to protein networks that play a role in abnormal cell growth, while hypertension is linked to protein networks for ion channels, transcription factors and metabolic enzymes.

With the upgraded network, we can make stronger predictions because we have a more complete picture of the interactions within a cell, said first author Edward Huttlin, instructor of cell biology at HMS. We can pick out statistical patterns in the data that might suggest disease susceptibility for certain proteins, or others that might suggest function or localization properties. It makes a significant portion of the human proteome accessible for study.

Launching point

The entire BioPlex network and accompanying data are publicly available, supporting both large-scale studies of protein interaction and targeted studies of the function of specific proteins.

Although the network serves as the largest collection of such data gathered to date, the authors caution it remains an incomplete model. The current pipeline expresses bait proteins in only one cell type (human embryonic kidney cells) grown under one set of conditions, for example, and distinct interactions may occur in different cell types or microenvironments.

As the network increases in size and more human proteins are used as baits, scientists can better judge the accuracy of each individual protein interaction by considering its context in the larger network. Isolating the same protein complex several times, each time using a different member as a bait, can provide multiple independent experimental observations to confirm each proteins membership.

Moreover, by using prey proteins as bait, many protein interactions can be observed in the opposite direction as well. Both of these scenarios greatly reduce the likelihood that particular interactions were identified due to chance. The team continues to add to BioPlex, with a target goal of around 10,000 bait proteins, which would cover half of the human genome and would further increase the predictive power of the network.

We certainly arent seeing all the interactions, but its a launching point. We think its important to continue to build this map, to see how much of it is reproduced in other cell types under different conditions, to see whether the interactions are similar or dynamic, Gygi said. Because whether youre interested in cancer or neurodegenerative disease, basic development or evolutionary fitnessyou can make new hypotheses and learn something from this network.

This work was supported by the National Institutes of Health (HG006673, DK098285), Biogen and the Canadian Institutes of Health Research.

Co-authors on the study included Raphael J. Bruckner, Joao A. Paulo, Joe R. Cannon, Lily Ting, Kurt Baltier, Greg Colby, Fana Gebreab, Melanie P. Gygi, Hannah Parzen, John Szpyt, Stanley Tam, Gabriela Zarraga, Laura Pontano-Vaites, Sharan Swarup, Anne E. White, Devin K. Schweppe, Ramin Rad, Brian K. Erickson, Robert A. Obar, K.G. Guruharsha, Kejie Li and Spyros Artavanis-Tsakonas.

Read this article:
Social networking for the proteome, upgraded | HMS - Harvard Medical School (registration)

Veterinary Biochemistry Analyzers Market Key … – Digital Journal – Digital Journal

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 05/19/2017 -- Veterinary Biochemistry Analyzers Market: Overview

Veterinary biochemistry analyzers enable testing to be performed quickly and accurately for immediate diagnosis and health check for animals. They are also used in emergency situation, and routine testing. Increasing incidences of disease outbreak in animals and technological advancements are expected to drive the veterinary biochemistry analyzers market. Additionally, growing awareness regarding animal health and rise in investment opportunities together form strong market prospects for veterinary biochemistry analyzers, especially in the developing countries.

View Report @ http://www.transparencymarketresearch.com/veterinary-biochemistry-analyzers-market.html

The threats such as foot and mouth disease (FMD), as well as agents that affect animals and humans, such as bovine tuberculosis and paratuberculosis, anthrax, avian influenza, bovine spongiform encephalopathy (BSE) and West Nile virus are responsible for rise in importance of need for veterinary disease diagnostics eventually propelling the market growth.

Most veterinary laboratories typically provide a basic panel of tests. The veterinary biochemistry analysis may be performed in-house at the veterinarian's clinic or at a specialized test facility in another location depending on the need of test type to be performed as well as availability of equipment in that particular facility. Advancements in the analyzers technology is anticipated to fuel fueled the market growth due to the availability of faster and cheaper microchips with increase in acceptance level of pet owners for laboratory testing.

Veterinary Biochemistry Analyzers Market: Segmentation

The global veterinary biochemistry analyzers market can be segmented on the basis of product type, test type, animal type, end-users and geography. Test types include clinical chemistry, critical care and blood gases, electrolytes, glucose, lactate and blood and urine tests. Other tests include: tests for anemia, endocrine function; cancer, viral pathogens such as calicivirus (CaCV), canine adenovirus type-1 (CAV-1), coronavirus, adenovirus, parvovirus, rotavirus, rabies, West Nile Virus, etc.; and bacteria and parasites such as E. coli, heartworm, cryptosporidia, hookworm, leptospirosis, leishmania, Lyme disease, tapeworm and roundworm. Chemical analysis of urine may include determination of specific gravity and pH level, measurement of the amount of glucose, protein, or fragmented blood cells, assisting in identification of injury, disease, or defects.

Analysis of the numbers and structure of blood cells is important in the diagnosis and monitoring of disease and infection. Blood samples are usually taken by the veterinarian or a veterinary technician for analysis. Product types include fully automated analyzers, semi-automated analyzers, hematology analyzers, urine analyzers amongst others.

End-users segment includes veterinary clinics, pet hospitals and animal research institutes. Companion animal and farm animal form two segments for animal type.

Veterinary Biochemistry Analyzers Market: Region-wise Outlook

Geographically, the veterinary biochemistry analyzers market across the globe can be segmented into four major regions, namely, North America, Europe, Asia Pacific and Rest of the World. North America is expected to lead the market with maximum share followed by Europe attributed to the increasing companion animal population and positive trends towards healthcare expenditure for animals in these regions.

Veterinary Biochemistry Analyzers Market: Key Entities

Major players contributing to the global veterinary biochemistry analyzers comprise Abaxis,Inc., Heska, Diagno-Vision Products Corporation, Idexx Laboratories, Inc., Mindray Medical International Limited, Neogen Corporation, Thermo Fischer Scientific, Virbac SA, Woodley Equipment Company Ltd., Zoetis, Inc.

Get accurate market forecast and analysis on the Veterinary Biochemistry Analyzers Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11888

Univerities such as the University of Minnesota Veterinary Diagnostic Laboratory (VDL), which is fully accredited by the American Association of Veterinary Laboratory Diagnosticians, provide quality diagnostic services such as bacteriology, necropsy, electron microscopy, serology, clinical chemistry, histopathology, endocrinology, virology, immunohistochemistry, parasitology, toxicology and molecular diagnostics. VDL is also engaged in training future diagnosticians and veterinarians.

For more information on this press release visit: http://www.sbwire.com/press-releases/veterinary-biochemistry-analyzers-market-key-trends-industry-forecast-2023-808303.htm

See original here:
Veterinary Biochemistry Analyzers Market Key ... - Digital Journal - Digital Journal

Grey’s Inferno? 6 Suggestions for the Grey’s Anatomy Firefighter Spin-Off – TV Guide (blog)

Now Playing Grey's Anatomy Is Spinning Off Into the Fire Department

Thirteen seasons in, Grey's Anatomy is still hot -- so hot that it's getting its second spin-off next season focused on Seattle's finest (and probably horniest) firefighters.

Details are scarce on the project, but what we do know: It received a straight-to-series order and will debut sometime next year. And in lieu of Shonda Rhimes, Grey's executive producer Stacy McKee will serve as showrunner -- which makes sense since she penned Thursday's fiery Season 13 finale. That's probably what sparked the idea! (#sorrynotsorry) The show's currently untitled, but don't worry, Shondaland, we've got some suggestions for you.

Add the new Fall shows to your Watchlist now!

1. Sea(ttle) of Flames Look, anything like Seattle Fire is too easy and Rhimes is going to want to distance herself as much as possible from comparisons to Dick Wolf's One Chicago franchise, which she's already halfway to replicating. Sea(ttle) of Flames covers a lot of territory: The fire element, duh, the city, and the city's wet reputation. I'll refrain from the low-hanging "Why do we need firefighters anyway with the rain?" joke.

2. Scarlett's BlazeThis is ideal if Shondaland wants to continue its colored moniker nomenclature. Scarlett's a shade of red and a name! Grey's very briefly introduced "Firefighter Carroll" (Stephanie Czajkowski) in Thursday's finale, but it's unclear if she'd be the spin-off's lead right now. Nevertheless, Scarlett could still be her first name, while "blaze" would be a nod to the eventual use of Bon Jovi's "Blaze of Glory" (you know Rhimes loves her music!).

Furthermore, Rhimes' new, generically titled legal drama For the People was formerly dubbed Mother Court (LOL) and Black's Law. Since the slow is slated for midseason, it's not too late to retroactively make this the ChiJu of the Greysverse and revert to Black's Law. (The eventual cop spin-off would have a blue-hued name, obviously.)

3. Grey's InfernoOr they could retain the "Grey's" name for easy-to-recognize familiarity in the age of Peak TV (and would it surprise anyone if Meredith discovered she had another sister at this point?). Plus, everyone knows the 10th circle of hell is Shondaland's catastrophe-prone Seattle.

4. Byrnes' Ashes Non-colored, no Grey relation, but still pun-tastic. Alternate, far-more-literal spelling: Burns' Ashes.

5. How to Get Away with PyromaniaIn a Law & Order: Criminal Intent-esque twist, the show would be told from the perspectives of both the people who start fires around Seattle and the firefighters who try to put them out. (Fun fact: Czajkowski guest-starred on How to Get Away with Murder in 2015.)

6. Hose Before Bros The spin-off will almost definitely feature a female lead to join the ranks of Shondaland badass leading ladies Meredith Grey, Olivia Pope, Annalise Keating, Addison Montgomery et al., and it will definitely cover the team's personal lives (the logline promises the show will follow "heroic firefighters as they risk their lives and their hearts both in the line of duty and off the clock"). After getting burned (!) by a former flame (!!), our heroine will have a renewed focus on her career, coining the titular mantra, but then a new hoseman joins the firehouse, and well, you know.

The Grey's spin-off will premiere next year.

More here:
Grey's Inferno? 6 Suggestions for the Grey's Anatomy Firefighter Spin-Off - TV Guide (blog)

‘Grey’s Anatomy’: Find out which doctor just left the show – USA TODAY

Jerrika Hinton took to Instagram to express just how grateful she is. USA TODAY

Spoiler alert! The following contains spoilers from Thursday's season finale ofGrey's Anatomy,"Ring of Fire."

Another doctor is leaving Grey Sloan Memorial Hospital.

In a bombastic finale to the show's 13th season, it was revealed that Dr. Stephanie Edwards (Jerrika Hinton) was alive after last week's cliffhanger, but also that she is leaving the hospital, and the show, after enduring burns during a traumatic night.

We'll miss you, Edwards!(Photo: Richard Cartwright, ABC)

Last week's episode found a rapist loose in the hospital, who first holds Edwards at knife-point, then sets a fire to attempt to escape the hospital and even takes a young girl hostage. Edwards is able to save the girl but suffers severe burns in the process. In the finale, confined to her hospital bed, Edwards tells her mentorDr. Richard Webber (James Pickens Jr.), "I quit."

And though Edwards will be missed, her method of exit is rare on a show known for its tragic deaths. In a goodbye note on her Instagram, Hinton noted how great it was that Edwards got to choose her own path.

"I am eternally thankful for five seasons of (Grey's Anatomy) and a graceful departure that underscores the courage it takes to choose yourself," Hinton wrote. "That Stephanie literally walks through fire to reach freedom her freedom inspires me. It also makes me curious: What does freedom look like for you, dear viewer? After all, its not only the heroics that make her brave, its her finally seeing (and seeking) a better path."

"You fans and viewers are some of the most devoted folks Ive ever met," she went on. "Thank you for your endless energy. Bosslady Shonda, Queen Debbie, and entire (Grey's Anatomy) cast and crew forever remain in my heart. The #Shondaland family is a mighty, winding forest. I look forward to seeing you all in another clearing."

See her whole note below.

Read or Share this story: https://usat.ly/2qB3lL4

Go here to see the original:
'Grey's Anatomy': Find out which doctor just left the show - USA TODAY

Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO … – GlobeNewswire (press release)

May 17, 2017 17:05 ET | Source: NewLink Genetics Corporation NewLink Infographic ASCO.pdf

AMES, Iowa, May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

An infographic accompanying this announcement is available athttp://www.globenewswire.com/NewsRoom/AttachmentNg/b945495b-6286-4184-881f-b4ea49aa46b4

The IDO pathway is a key immuno-oncology target and NewLink Genetics has two separate and distinct IDO pathway inhibitors in clinical development.Indoximod, which is wholly owned by NewLink Genetics, has a proposed differentiated mechanism within the IDO pathway and acts as a tryptophan mimetic having a direct effect on immune cells to reverse immune suppression used by cancer to protect itself. Navoximod is our direct enzymatic inhibitor of IDO and is partnered with Genentech/Roche, said Charles J. Link, Jr., M.D., Chief Executive Officer and Chief Scientific Officer of NewLink Genetics.

Indoximod in combination with the therapeutic cancer vaccine, PROVENGE

Results from a randomized, double-blind, placebo-controlled, multi-institutional Phase 2 investigator initiated study with indoximod in combination with the therapeutic cancer vaccine, PROVENGE (sipuleucel-T), for patients with metastatic castration resistant prostate cancer will be presented as a poster (Abstract number 3066) by Gautam Gopalji Jha, M.D., Adjunct Assistant Professor, Division of Hematology and Oncology, University of Minnesota, at ASCO in Chicago on Monday, June 5, 2017, 8:00 a.m. 11:30 a.m. CT, titled, A phase 2 randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC).

In the study, forty-six patients were randomized into two arms to receive either twice daily oral indoximod (n=22) or placebo (n=24) for 6 months beginning the day after the third and final PROVENGE infusion. Conclusions indicate that treatment with the IDO pathway inhibitor, indoximod, post PROVENGE therapy, leads to significant improvement in radiographic progression free survival (rPFS) when compared to placebo and is well-tolerated.

Key findings presented from the study include:

These data further support the hypothesis that targeting the IDO Pathway in combination with a broad backbone of treatment regimens including chemotherapy, anti-PD-1 antibodies and therapeutic vaccines across multiple indications has the potential to provide meaningful clinical benefit without compromising tolerability, commented Nicholas N. Vahanian, M.D., President and Chief Medical Officer of NewLink Genetics.

Navoximod in combination with TECENTRIQ (atezolizumab) in multiple solid tumors

Initial data from a Phase 1b dose-escalation study of navoximod in combination with TECENTRIQ for patients with locally advanced or metastatic solid tumors conducted by our partner, Genentech/Roche, will be presented in an oral presentation (Abstract number 105) by Howard A. Skip Burris, III, M.D., President Clinical Operations and Chief Medical Officer, Sarah Cannon Research Institute, at ASCO in Chicago on Sunday, June 4, 2017, 10:24 a.m. CT. The presentation is titled, A phase 1b dose-escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients with locally advanced or metastatic solid tumors.

This Phase 1b, open-label, dose-escalation study is designed to characterize safety and tolerability. Secondary objectives include identifying a maximum tolerated dose (MTD) and recommended Phase 2 dose, and evaluating pharmacokinetics, pharmacodynamics, and anti-tumor activity. Patients were given TECENTRIQ (1200 mg IV every 3 weeks) and escalating doses of navoximod (orally twice daily, for 21 days) using a standard 3+3 design. Initial results from this study (n=52, non-selected heterogeneous population during the dose escalation) found the combination was generally well-tolerated, with peripheral IDO1 modulation, and some early activity signals. Patients were previously treated with prior systemic therapies with a median number of 3 and a range of 1-9. Two patients also received prior immunotherapy.

The design of the trial includes the initial dose-escalation phase reported in this abstract, followed by disease-specific expansion cohorts (enrollment target is 305 patients) for patients with select tumor types including non-small-cell lung cancer (NSCLC), renal cell cancer (RCC), urothelial bladder cancer (UBC), triple negative breast cancer (TNBC), to further evaluate safety, response, and peripheral and tumor pharmacodynamics. Updates for this study will continue to be reported by Genentech/Roche.

Dr. Vahanian continued, We are encouraged by the clinical profile for the combination of navoximod and atezolizumab from the first phase of this combination trial and look forward to the data for the disease-specific expansion cohorts which are currently accruing patients.

About NewLink Genetics Corporation

NewLink Geneticsis a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.NewLink Genetics'product candidates are designed to harness multiple components of the immune system to combat cancer.For more information, please visit http://www.newlinkgenetics.com.

PROVENGE is a registered trademark of Dendreon/Valeant Pharmaceuticals International, Inc. TECENTRIQ is a registered trademark of Genentech, Inc.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties.All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact.Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics Annual Report on Form 10-K for the year endedDecember 31, 2016and other reports filed with theU.S. Securities and Exchange Commission(SEC).The forward-looking statements in this press release represent NewLink Genetics views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change.However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.

Related Articles

Read more from the original source:
Data from Clinical Studies of NewLink Genetics' Two Distinct IDO ... - GlobeNewswire (press release)